109 related articles for article (PubMed ID: 15156449)
1. Atazanavir: new option for treatment of HIV infection.
Havlir DV; O'Marro SD
Clin Infect Dis; 2004 Jun; 38(11):1599-604. PubMed ID: 15156449
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
3. Atazanavir for the treatment of human immunodeficiency virus infection.
Busti AJ; Hall RG; Margolis DM
Pharmacotherapy; 2004 Dec; 24(12):1732-47. PubMed ID: 15585441
[TBL] [Abstract][Full Text] [Related]
4. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
6. Atazanavir.
Orrick JJ; Steinhart CR
Ann Pharmacother; 2004 Oct; 38(10):1664-74. PubMed ID: 15353575
[TBL] [Abstract][Full Text] [Related]
7. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
8. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Macassa E; Delaugerre C; Teglas JP; Jullien V; Tréluyer JM; Veber F; Rouzioux C; Blanche S
Pediatr Infect Dis J; 2006 Sep; 25(9):809-14. PubMed ID: 16940839
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
Cleijsen RM; van de Ende ME; Kroon FP; Lunel FV; Koopmans PP; Gras L; de Wolf F; Burger DM
J Antimicrob Chemother; 2007 Oct; 60(4):897-900. PubMed ID: 17704117
[TBL] [Abstract][Full Text] [Related]
10. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
Colonno R; Rose R; McLaren C; Thiry A; Parkin N; Friborg J
J Infect Dis; 2004 May; 189(10):1802-10. PubMed ID: 15122516
[TBL] [Abstract][Full Text] [Related]
11. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
Winston A; Bloch M; Carr A; Amin J; Mallon PW; Ray J; Marriott D; Cooper DA; Emery S
J Antimicrob Chemother; 2005 Aug; 56(2):380-7. PubMed ID: 15996972
[TBL] [Abstract][Full Text] [Related]
12. Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Moltó J; Santos JR; Valle M; Miranda C; Miranda J; Blanco A; Negredo E; Clotet B
Ther Drug Monit; 2007 Oct; 29(5):648-51. PubMed ID: 17898658
[TBL] [Abstract][Full Text] [Related]
13. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
14. Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Vergani B; Cicero ML; Vigano' O; Sirianni F; Ferramosca S; Vitiello P; Di Vincenzo P; Pia De Pasquale M; Galli M; Rusconi S
J Clin Virol; 2008 Feb; 41(2):154-9. PubMed ID: 18024202
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study.
Martin DE; Galbraith H; Schettler J; Ellis C; Doto J
Clin Ther; 2008 Oct; 30(10):1794-805. PubMed ID: 19014835
[TBL] [Abstract][Full Text] [Related]
16. Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
Stebbing J; Nathan B; Jones R; McKenna A; Powles T; Bower M; Holmes P; Gazzard B; Nelson M
AIDS; 2007 Aug; 21(13):1826-8. PubMed ID: 17690587
[TBL] [Abstract][Full Text] [Related]
17. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Wirtz V; Rightmire A; Odeshoo L; McLaren C
AIDS; 2006 Mar; 20(5):711-8. PubMed ID: 16514301
[TBL] [Abstract][Full Text] [Related]
18. Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Di Giambenedetto S; De Luca A; Villani P; Bacarelli A; Ragazzoni E; Regazzi M; Cauda R; Navarra P
HIV Med; 2008 Apr; 9(4):239-45. PubMed ID: 18366448
[TBL] [Abstract][Full Text] [Related]
19. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
von Hentig N; Babacan E; Lennemann T; Knecht G; Carlebach A; Harder S; Staszewski S; Haberl A
J Antimicrob Chemother; 2008 Sep; 62(3):579-82. PubMed ID: 18477709
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
Sahloff EG; Duggan JM
Ann Pharmacother; 2006 Oct; 40(10):1731-6. PubMed ID: 16968825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]